SCHEMBL4877137

SCHEMBL4877137

Cc1ccccc1-c1ccc2cc(-c3c(-c4ccccc4)c4sc(C(=O)O)cc4n3CC(=O)N3CCC(N4CCOCC4)CC3)ccc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 1/20 0.39
CDYL2 Q8N8U2 1/20 0.39
CDYL Q9Y232 1/20 0.39
CDY1; CDY1B Q9Y6F8 1/20 0.39
ACHE P22303 1/20 0.38
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
GRIN2B Q13224 1/20 0.37
POLB P06746 2/20 0.36
GAA P10253 2/20 0.36
TSHR P16473 1/20 0.36
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
GSK3B P49841 2/20 0.35
DYRK1A Q13627 2/20 0.35
KCNH2 Q12809 1/20 0.35
SMO Q99835 1/20 0.35
KDM4E B2RXH2 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870801 0.92 CBX7 (0.39) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4877126 0.91 CBX7 (0.37) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4874715 0.90 BRD4 (0.38) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4877781 0.89 ACHE (0.43) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4876725 0.88 KMT2A (0.41) GRIN2BPOLBGAATSHRMAPT
SCHEMBL4873226 0.88 CBX7 (0.39) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4878179 0.88 PIK3CA (0.42) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4870899 0.88 ACHE (0.40) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4875250 0.88 KMT2A (0.41) GRIN2BPOLBGAATSHRMAPT
SCHEMBL4873998 0.86 TRPV4 (0.40) CBX7CDYL2CDYLCDY1; CDY1BACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 CBX7 2500/4885CDYL2 4283/4885CDYL 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.